Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies

Cancer Immunology, Immunotherapy

Volumn 66, Issue 9, 2017, Pages 1113-1121

  Hegde, Upendra P ^a   Mukherji, Bijay ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

CAR T cells; ICI; Immunotherapy; Tumor

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GILVETMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ADOPTIVE TRANSFER; ADVERSE EVENT; ANTIGEN SPECIFICITY; B LYMPHOCYTE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG DESIGN; EFFECTOR CELL; HUMAN; KIDNEY CANCER; MELANOMA; MERKEL CELL CARCINOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; IMMUNOLOGY; NEOPLASM; PROCEDURES; TISSUE ENGINEERING;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES; TISSUE ENGINEERING;

EID: 85018692731     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-2007-x     Document Type: Review

References (71)

1. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of Cancer. Nat Rev Cancer 12:278–287
2. Herr HW, Morales A (2008) History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 179(1):53–56
3. Rosenberg SA, Yang JC, Sherry RM et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550–4557
4. Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348:56–61
5. Gill S, June CH (2015) Going viral chimeric antigen receptor T cell therapy for hematological malignancies. Immunol Rev 263:68–89
6. Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319
7. Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell cancer. N Engl J Med 375:1823–1833
8. Holzinger A, Barden M, Abken H (2016) The growing world of CAR T cell trials: a systematic review. Cancer Immunol Immunother 65:1433–1450
9. Kuwana Y, Asakura Y, Utsunomiya N et al (1987) Expression of chimeric receptor composed of immunoglobulin-derived V regions and T cell receptor-derived C regions. Biochem Biophys Res Commun 149:960–968
10. Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T cell receptor chimeric molecules as functional receptors with antibody specificity. Proc Natl Acad Sci (USA) 86:10024–10028
11. Peggs KS, Quezada SA, Chambers CA et al (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717–1730
12. Hwu P, Yang JC, Cowherd J et al (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369–3373
13. Kershaw MH, Westwood JA, Parker LL et al (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for cancer. Clin Cancer Res 12:6106–6115
14. Park JR, DiGuisto DL, Slovak M et al (2007) Adoptive transfer of chimeric antigen receptor redirected cytolytic T lymphocytes clones in patients with neuroblastoma. Mol Ther 15:825–833
15. Till BG, Jensen MC, Wang J et al (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112:2261–2271
16. Pule MA, Savoldo B, Myers GD et al (2008) Virus specific T cells engineered to co express tumor specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264–1270
17. Jensen MC, Popplewell L, Cooper LJ et al (2010) Antitransgene rejection responses contributed to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transpl 16:1245–1256
18. Kochenderfer JN, Wilson WH, Janik JE et al (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:4099–4102
19. Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733
20. Brentjens RJ, Riviere I, Park JH et al (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118:4817–4828
21. Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509–1518
22. Cruz CR, Micklethwaite KP, Savoldo B et al (2013) Infusion of donor derived CD19-redirected virus specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase I study. Blood 122:2965–2973
23. Maude SL, Teachey DT, Porter DL et al (2015) CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125:4017–4023
24. Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in Leukemia. N Engl J Med 371:1507–1517
25. Curran KJ, Riviere I, Silverman LB et al (2015) Multi-center clinical trial of CAR T cells in pediatric/young adult patients with relapsed B-cell ALL [ASH abstract 2533]. Blood 126(23 suppl)
26. Park JH, Geyer MB, Brentjens R (2016) CD19 targeted CAR T-cell therapeutics for Chimeric antigen receptor (CAR) T cell therapeutics for hematological malignancies. Interpreting clinical outcomes to date. Blood 127:3312–3320
27. Barrett DM, Teachey DT, Grupp SA (2014) Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 26:43–49
28. Davila MD, Rivere I, Wang X et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoid leukemia. Sci Transl Med 6(224):224ra25
29. Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127:3321–3330
30. Bonifant CL, Jackson HJ, Brentjens RJ et al (2016) Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 3:16011
31. Morgan RA, Yang JC, Kitano M et al (2010) Case report of a serious adverse event following the administration of T-cells transduced with chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843–851
32. Linsley P, Greene JL, Bradshaw J et al (1992) Co expression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 176:1595–1604
33. Walunas TL, Lenschow DJ, Bakker CY et al (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405–413
34. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459–465
35. Leach DR, Krummel LF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736
36. Yang JC, Hughes M, Kammula U et al (2007) Ipilimumab (anti-CTLA-4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30(8):825–830
37. Weber J, O’Day S, Urba W et al (2008) Phase 1/II study of Ipilimumab for patients with metastatic melanoma. J Clin Oncol 26:5950–5956
38. Hodi FS, Butler M, Oble DA et al (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105:3005–3010
39. Camacho LH, Antonia S, Sosman J et al (2009) Phase I/II trial of Tremelimumab in patients with metastatic melanoma. J Clin Oncol 27:1075–1081
40. Sharma P, Wagner K, Wolchok JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11:805–812
41. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
42. Prieto PA, Yang JC, Sherry RM et al (2012) CTLA-4 blockade with Ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039–2047
43. Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889–1894
44. Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887–3895
45. Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034
46. Dong H, Gefeng Z, Tamada K et al (1999) B7-H1, a third member of the B7 family, co-stimulates T cell proliferation and interleukin-10 secretion. Nat Med 5:1365–1369
47. Dong H, Strome SE, Salomao DR et al (2002) Tumor associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–799
48. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
49. Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465
50. Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144
51. Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving Nivolumab. J Clin Oncol 32:1020–1030
52. Ribas A, Hamid O, Daud A et al (2016) Association of Pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600–1609
53. Hodi FS, Klugger H, Sznol M et al (2016) Durable long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Abstract CT001. In: Proceedings American Association Cancer Research 107th Annual Meeting 2016, April 16–20, New Orleans
54. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372:320–333
55. Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med 369:122–233
56. Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and Ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017
57. Larkin J, Chiarion-Sileni V, Gonzalez R et al (1015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34
58. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus Dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526
59. Powles T, Eder JP, Fine GD et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558
60. Nghiem PT, Bhatia S, Lipson EJ (2016) PD-1 blockade with Pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 374:2542–2551
61. Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to anti-PD-L1 antibody MPDL3280A in cancer. Nature 515:563–567
62. Green MR, Monti S, Rodig S et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction with JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B cell lymphoma. Blood 116:3268–3277
63. Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single agent anti-programmed death-1 (MDX1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167–3175
64. Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive resistance. Nature 515:568–571
65. Snyder A, Makarov V, Merghoub T et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–2199
66. Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348(6230):69–74
67. Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681–6688
68. Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer immunother Sci 342:1432–1433
69. Chapuis AG, Lee SM, Thompson JA et al (2016) Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med 213:1133–1139
70. Chun TW, Fauci AS (2012) HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 26:1261–1268
71. Deininger M (2012) Stem cell persistence in chronic myeloid leukemia. Leuk Suppl 1(Suppl 2):546–548